10th National VBP Round Results Announced: Contracts Worth Over RMB1.3 Billion
DrugMedical Device

10th National VBP Round Results Announced: Contracts Worth Over RMB1.3 Billion

Xtalpi Inc. Partners with Amazon Web Services to Accelerate Life Sciences Innovation
CompanyDeals

Xtalpi Inc. Partners with Amazon Web Services to Accelerate Life Sciences Innovation

Jiangxi Jemincare Group Gets NMPA Approval for Prostate Cancer Drug JMX-2006
CompanyDrug

Jiangxi Jemincare Group Gets NMPA Approval for Prostate Cancer Drug JMX-2006

CARsgen Therapeutics Initiates Trial for Universal CAR-T Therapy KJ-C2219 in China
CompanyDrug

CARsgen Therapeutics Initiates Trial for Universal CAR-T Therapy KJ-C2219 in China

We Doctor Holdings Limited Files for IPO on Hong Kong Stock Exchange
CompanyDeals

We Doctor Holdings Limited Files for IPO on Hong Kong Stock Exchange

Shinva Medical Instrument to Acquire Stake in Wuhan Zhongzhi Biotechnologies for IVD Expansion
CompanyDeals

Shinva Medical Instrument to Acquire Stake in Wuhan Zhongzhi Biotechnologies for IVD Expansion

Hinova Pharmaceuticals' HP568 Earns FDA Clinical Trial Approval for ER+/HER2- Breast Cancer
CompanyDrug

Hinova Pharmaceuticals’ HP568 Earns FDA Clinical Trial Approval for ER+/HER2- Breast Cancer

CanSino Biologics' Menhycia Receives Market Approval in Indonesia
CompanyDrug

CanSino Biologics’ Menhycia Receives Market Approval in Indonesia

CSPC Pharmaceutical Group Receives NMPA Approval for SYH9016 Clinical Study in Solid Tumors
CompanyDrug

CSPC Pharmaceutical Group Receives NMPA Approval for SYH9016 Clinical Study in Solid Tumors

MicuRx Pharmaceuticals' MRX-5 Receives FDA Orphan Drug Designation for NTM Infections
CompanyDrug

MicuRx Pharmaceuticals’ MRX-5 Receives FDA Orphan Drug Designation for NTM Infections

Hengrui Pharmaceuticals and IDEAYA Biosciences Ink Licensing Deal for SHR-4849
CompanyDeals

Hengrui Pharmaceuticals and IDEAYA Biosciences Ink Licensing Deal for SHR-4849

CARsgen Therapeutics' Satricabtagene Autoleucel Shows Positive Results in Phase II Study
CompanyDrug

CARsgen Therapeutics’ Satricabtagene Autoleucel Shows Positive Results in Phase II Study